We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+3.29%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$2.76B
AUM Growth
+$170M
Cap. Flow
+$156M
Cap. Flow %
5.64%
Top 10 Hldgs %
29.4%
Holding
140
New
9
Increased
43
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$48.9M
2
ADPT icon
Adaptive Biotechnologies
ADPT
+$26.6M
3
PODD icon
Insulet
PODD
+$25.1M
4
CHRS icon
Coherus Oncology
CHRS
+$21M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$14.7M

Top Sells

Rank Stock Value
1
WMGI
Wright Medical Group Inc
WMGI
+$29M
2
CVET
Covetrus, Inc. Common Stock
CVET
+$17.8M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$16.4M
4
IFRX icon
InflaRx
IFRX
+$8.5M
5
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$7.18M

Sector Composition

Rank Sector Weight
1 Healthcare 86.18%
2 Consumer Staples 0.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COLL icon
51
Collegium Pharmaceutical
COLL
$956M
$20.7M 0.75%
1,577,893
– –
ZLAB icon
52
Zai Lab
ZLAB
$2.62B
$19.2M 0.69%
550,000
+136,600
+33% +$4.02M
TVTX icon
53
Travere Therapeutics
TVTX
$5.78B
$19.1M 0.69%
950,000
+120,000
+14% +$2.37M
PHAS
54
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$18.7M 0.68%
1,423,256
+283,256
+25% +$3.47M
ALDR
55
DELISTED
Alder Biopharmaceuticals
ALDR
$18.4M 0.67%
1,562,300
+2,300
+0.1% +$27.8K
XENT
56
DELISTED
Intersect ENT, Inc
XENT
$18M 0.65%
790,000
+325,000
+70% +$8.77M
ALLK
57
DELISTED
Allakos
ALLK
$17.5M 0.63%
404,000
– –
WST icon
58
West Pharmaceutical
WST
$24.9B
$17.2M 0.62%
137,500
+12,500
+10% +$1.48M
CELG
59
DELISTED
Celgene Corp
CELG
$17.1M 0.62%
185,150
– –
SAGE
60
DELISTED
Sage Therapeutics
SAGE
$16.9M 0.61%
92,500
– –
SGEN
61
DELISTED
Seagen Inc. Common Stock
SGEN
$16.7M 0.61%
242,000
– –
GH icon
62
Guardant Health
GH
$22.6B
$16.4M 0.59%
190,000
+10,000
+6% +$764K
AXNX
63
DELISTED
Axonics, Inc. Common Stock
AXNX
$16.4M 0.59%
400,000
– –
ODT
64
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$15.8M 0.57%
430,000
-15,000
-3% -$359K
BOLD
65
DELISTED
Audentes Therapeutics, Inc
BOLD
$15.5M 0.56%
410,000
-112,500
-22% -$4.32M
BHVN
66
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$15M 0.54%
343,500
+83,500
+32% +$4.71M
GBT
67
DELISTED
Global Blood Therapeutics, Inc.
GBT
$13.9M 0.5%
265,000
+20,000
+8% +$1.15M
KYNB
68
Kyntra Bio
KYNB
$29.4M
$13.8M 0.5%
12,240
– –
A icon
69
Agilent Technologies
A
$41.2B
$13.7M 0.49%
182,800
– –
TBIO
70
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$12.7M 0.46%
1,009,179
– –
NVRO
71
DELISTED
NEVRO CORP.
NVRO
$12.7M 0.46%
195,500
+160,800
+463% +$10M
OBSV
72
DELISTED
ObsEva SA Ordinary Shares
OBSV
$12.7M 0.46%
1,120,000
– –
FOLD
73
DELISTED
Amicus Therapeutics
FOLD
$12.5M 0.45%
1,000,000
– –
IMMU
74
DELISTED
Immunomedics Inc
IMMU
$12.4M 0.45%
895,000
+95,000
+12% +$1.43M
NVCR icon
75
NovoCure
NVCR
$1.91B
$12.3M 0.45%
195,000
– –
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2019 Portfolio in Review

As of Q2 2019, Rock Springs Capital Management held 140 positions worth $2.76B, up 6.6% from $2.59B the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Rock Springs Capital Management deployed $156M of net new capital in Q2 2019, opening 9 new positions and adding to 43 existing holdings. Its largest new stake was Bristol-Myers Squibb: 1,050,000 shares worth $47.6M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 85% a quarter earlier, followed by Consumer Staples.

On the sell side, the largest reduction was Covetrus, Inc. Common Stock, an estimated $17.8M trimmed.

  • Rock Springs Capital Management's largest Q2 2019 buy was Bristol-Myers Squibb: 1,050,000 shares worth $47.6M.
  • Rock Springs Capital Management added most to Coherus Oncology in Q2 2019, an estimated $21M increase.
  • Rock Springs Capital Management's biggest Q2 2019 reduction was Covetrus, Inc. Common Stock, cutting an estimated $17.8M.
  • Rock Springs Capital Management fully exited Wright Medical Group Inc in Q2 2019, selling an estimated $29M.
  • Rock Springs Capital Management's ten largest holdings make up 29% of its $2.76B portfolio in Q2 2019.
  • Rock Springs Capital Management opened 9 new positions and closed 5 in Q2 2019.
  • Rock Springs Capital Management's portfolio value rose 6.6% quarter-over-quarter to $2.76B.

Based on Rock Springs Capital Management's 13F filing for Q2 2019, filed 14 Aug 2019.